INmune Bio Reports $1.3 Million Net Loss in Q2 2026, Focuses on CORDStrom Development

INmune Bio, Inc. reported its financial results for the second quarter and first half of 2026, revealing a net loss of $1.3 million for the three months ended June 30, 2026, a significant decrease from a net loss of $24.5 million in the same period of 2025. For the six months ended June 30, 2026, the company recorded a net loss of $6.7 million, down from $34.2 million in the prior year. The company did not generate any revenue during the second quarter or the first half of 2026, compared to $50,000 in revenue for the first half of 2025. Total operating expenses for the second quarter were $1.5 million, a substantial reduction from $24.6 million in the prior year, primarily due to a decrease in research and development expenses.

The company’s research and development expenses for the second quarter of 2026 were $(803,000), a notable decrease from $5.8 million in the same quarter of 2025. This reduction was attributed to a $4.2 million increase in research and development tax rebates, as well as lower expenses related to the Alzheimer’s clinical program, which had completed its Phase 2 trial in 2025. General and administrative expenses remained relatively stable at approximately $2.3 million for both the second quarters of 2026 and 2025. The company’s total cash and cash equivalents at the end of the second quarter were $18.4 million, down from $24.8 million at the end of 2025.

In terms of strategic developments, INmune Bio has been focusing on its lead product candidate, CORDStrom, which is aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). The company is preparing for regulatory submissions in the UK and EU by the end of 2026 and early 2027, respectively. Additionally, the company has entered into an amended agreement with Anthony Nolan to secure a long-term supply of umbilical cord tissue for CORDStrom, which may also support future product candidates.

Operationally, INmune Bio has been actively managing its expenses and cash flow. The company reported a decrease in cash used in operating activities to $6.6 million for the first half of 2026, compared to $14.2 million in the same period of 2025. The company also received approximately $4.4 million in cash rebates from government-sponsored research and development incentive programs in Australia and the UK during the first half of 2026, which has bolstered its liquidity. However, the company has raised substantial doubt about its ability to continue as a going concern, projecting that its existing cash will be insufficient to sustain operations for the next year without additional financing.

Looking ahead, INmune Bio plans to continue its focus on advancing its product candidates through clinical development and regulatory approval processes. The company is exploring various financing strategies, including public or private equity sales, debt financing, and potential collaborations or licensing arrangements, to secure the necessary funding for its operations. The company acknowledges the uncertainty surrounding its ability to raise additional capital and the potential impact on its business and financial condition.